Holen Sie sich die Stockscreener-App
211.92
0.72%
1.52
Vorhandelsmarkt:
211.34
-0.58
-0.27%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$210.40
Offen:
$210.14
24-Stunden-Volumen:
4.33M
Relative Volume:
0.80
Marktkapitalisierung:
$374.37B
Einnahmen:
$58.33B
Nettoeinkommen (Verlust:
$3.73B
KGV:
100.91
EPS:
2.1
Netto-Cashflow:
$18.24B
1W Leistung:
+1.71%
1M Leistung:
+8.55%
6M Leistung:
+1.38%
1J Leistung:
+7.95%
1-Tages-Spanne:
$208.99
$212.16
1-Wochen-Bereich:
$205.49
$212.16
52-Wochen-Spanne:
$163.81
$218.66
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Vergleichen Sie ABBV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
211.92 | 371.68B | 58.33B | 3.73B | 18.24B | 2.10 |
|
LLY
Lilly Eli Co
|
735.19 | 656.73B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.06 | 426.69B | 90.62B | 22.66B | 18.18B | 9.35 |
|
NVS
Novartis Ag Adr
|
126.64 | 244.98B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
85.48 | 210.11B | 63.43B | 16.42B | 14.72B | 6.49 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
Stock Analysis | Abbvie OutlookMixed Signals Amid Optimistic Analysts and Strong Fundamentals - AInvest
Intraday pattern recognizer results for AbbVie Inc.July 2025 Macro Moves & Reliable Price Breakout Signals - Newser
Will AbbVie Inc. bounce back from current supportDay Trade & Weekly Return Optimization Plans - Newser
Combining machine learning predictions for AbbVie Inc.Stop Loss & Fast Gaining Stock Strategy Reports - Newser
AbbVie’s Strategic Acquisitions and Trial Success Fuel 0.72% Rally Despite 102nd-Ranked 920M Volume - AInvest
Strategic Implications of AbbVie’s Elahere Approval in Canada: A New Era for Oncology Growth and Market Access - AInvest
AbbVie's Elahere gains approval in Canada for ovarian cancer - Seeking Alpha
Visual trend scoring systems applied to AbbVie Inc.Trade Entry Summary & Real-Time Buy Zone Alerts - Newser
AbbVie HIV Drugs Being Tested as Possible Coronavirus Antidote - TheStreet
Healthcare Valuations Near Multi-Year Lows Suggest Risk–Reward Asymmetry - Investing.com
AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference - Investing News Network
AbbVie Inc. (ABBV) Acquires Psychedelic Drug Developer Gilgamesh for $1.2B, Enters Mental Health Market - MSN
Explore the human side of the health journey in AbbVie’s I Am campaign - Medical Marketing and Media
Visual analytics tools that track AbbVie Inc. performanceFed Meeting & Real-Time Sentiment Analysis - Newser
AbbVie to invest $195 million in new North Chicago pharmaceutical facility - Chicago Construction News
AbbVie (ABBV) Stock Analysis: Price Target & Market OutlookNews and Statistics - IndexBox
Is AbbVie Inc. backed by strong institutional buyingInsider Buying & AI Enhanced Market Trend Forecasts - خودرو بانک
Is AbbVie Stock Underperforming the S&P 500? - MSN
How to escape a deep drawdown in AbbVie Inc.2025 Big Picture & Real-Time Price Movement Reports - Newser
Analyzing recovery setups for AbbVie Inc. investorsGDP Growth & Fast Gain Stock Trading Tips - Newser
Analyzing drawdowns of AbbVie Inc. with statistical toolsTrade Exit Summary & Verified Stock Trade Ideas - Newser
Why AbbVie's Workplace Excellence Drives Long-Term Value for Investors - AInvest
Key metrics from AbbVie Inc.’s quarterly dataInflation Watch & Target Return Focused Picks - Newser
AbbVie Named to 2025 Best Workplaces in Asia List by Great Place To Work - Yahoo Finance
What indicators show strength in AbbVie Inc.2025 Retail Activity & Verified Entry Point Signals - Newser
What recovery options are there for AbbVie Inc.2025 Stock Rankings & Smart Money Movement Tracker - Newser
Pharma and Industrial Sector Catalysts: Evaluating AbbVie and Hawkins' Strategic Momentum - AInvest
What machine learning models say about AbbVie Inc.Weekly Trend Summary & Real-Time Stock Price Movement Reports - Newser
Signal strength of AbbVie Inc. stock in tech scannersMarket Volume Summary & Free Verified High Yield Trade Plans - Newser
Tools to assess AbbVie Inc.’s risk profile2025 Top Gainers & Technical Pattern Based Signals - Newser
Key deals this week: Hawkins, Canada Goose, AbbVie, Verint and more (BX:NYSE) - Seeking Alpha
Is AbbVie Inc. trending in predictive chart models2025 Performance Recap & Reliable Intraday Trade Plans - Newser
Is AbbVie Stock Underperforming The S&P 500? - Barchart.com
Quantitative breakdown of AbbVie Inc. recent movePortfolio Value Report & Low Risk High Win Rate Stock Picks - Newser
BeOne Preps For Sonrotoclax MCL Filing, With Sights Set On AbbVie/Roche’s Territory - insights.citeline.com
Detecting price anomalies in AbbVie Inc. with AIWeekly Risk Summary & Reliable Volume Spike Trade Alerts - Newser
AbbVie’s Promising Study on ABBV-453 for Multiple Myeloma: A Potential Game-Changer - TipRanks
AbbVie Inc. stock prediction for this weekMarket Activity Recap & Precise Swing Trade Entry Alerts - Newser
AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin - Seeking Alpha
ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025? - sharewise.com
Will a bounce in AbbVie Inc. offer an exitWeekly Trend Summary & Technical Entry and Exit Tips - Newser
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.50%
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):